课题基金 / 基金详情

SYNTHETIC VACCINE AGAINST SHIGELLOSIS II--SHIGELLA SONNEI

SYNTHETIC VACCINE AGAINST SHIGELLOSIS II--SHIGELLA SONNEI
抗志贺氏菌 II 型合成疫苗--宋内志贺氏菌
批准号:
6162489
负责人:
V POZSGAY
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

V POZSGAY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Shigella sonnei is a major causative organism of shigellosis worldwide, that appears the most prevalent of Shigellae in developed countries. We are developing synthetic oligosaccharide-based immunogens as possible vaccine candidates against this organism using an approach similar to the synthetic vaccine project targeting a conjugate vaccine against S. dysenteriae type 1. The O-SP of S. sonnei consists of a disaccharide repeating unit containing the unique sugars 2-acetamido-2-deoxy-l-altruronic acid and 2-acetamido-4-amino-2,4,6-trideoxy-d-galactose in a- and b-linked form, respectively. Using nuclear magnetic resonance spectroscopy we found that this polysaccharide has a zwitterionic structure with opposite charges at each consecutive residue. Starting from l-glucose and d-glucosamine, we synthesized the monosaccharide components of this polysaccharide the first time as their methyl glycosides in their natural anomeric configuration. NMR studies indicated that the trideoxy-galactose component exists in the 4C1 conformation whereas the conformations of the altruronic acid derivatives depend on their substitution pattern. The free uronic acid exists as an equilibrium mixture of the 4C1 and 1C4 chair conformers. We published complete assignments for the 1H and 13C NMR spectra of the O-SP and presented evidence that both pyranose residues in the polysaccharide exist in the 4C1 conformation. We have designed synthetic schemes for the assembly of the disaccharide repeating unit and for larger oligosaccharides of the O-SP of S. sonnei.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SYNTHETIC VACCINE AGAINST SHIGELLOSIS
ISOLATION AND PURIFICATION OF SUBUNIT B OF SHIGA TOXIN
ISOLATION AND PURIFICATION OF SUBUNIT B OF SHIGA TOXIN
SYNTHETIC VACCINE AGAINST SHIGELLOSIS
海外基金